Melanoma: diagnóstico y tratamiento

1 International Agency for Research on Cancer, WHO. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. 2013. http://globocan.iarc.fr (accessed Nov 29, 2017).

2 International Agency for Research on Cancer, WHO. CI5: cancer incidence in five continents. 2014. http://ci5.iarc.fr (accessed Nov 29, 2017).

3 Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136: 1161−71.

4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7−30.

5 Crocetti E, Mallone S, Robsahm TE, et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2179−90.

6 Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271−89.

7 Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 2011; 107: 362−66.

8 Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345: e4757.

9 Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol Clin 2009; 27: 205−14.

10 van der Leest RJ, Flohil SC, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 1053−62.

11 Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol 2015; 172: 885−915.

12 Watts CG, Dieng M, Morton RL, et al. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol 2015; 172: 33−47.

13 Badenas C, Aguilera P, Puig-Butille KA, Carrera C, Malvehy J, Puig S. Genetic counselling in melanoma. Dermatol Ther 2012; 25: 397–402.

14 American Cancer Society. Genetic counselling and testing for people at high risk of melanoma. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-prevention/genetic-counselingand-testing-for-people-at-high-risk-of-melanoma.html (accessed May 19, 2018).

15 Armstrong BK, Cust AE. Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: a perspective on Fears et al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. American Journal of Epidemiology 1977; 105: 420−427.Cancer Epidemiol 2017; 48: 147−56.

16 Jimbow K, Roth SI, Fitzpatrick TB, Szabo G. Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscope studies. J Cell Biol 1975;66: 663−70.

17 Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373: 1926−36.

18 Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415−21.

19 Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251−63.

20 Berger MF, Hodis E, Heffernan TP, et al. Melanoma genoma sequencing reveals frequent PREX2 mutations. Nature 2012;485: 502−06.

21 Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012; 44: 1006−14.

22 Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015; 161: 1681−96.

23 Noonan FP, Zaidi MR, Wolnicka-Glubisz A, et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun 2012; 3: 884−94.

24 Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239−71.

25 Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014−23.

26 Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017; 19: 1189−201.

27 Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22: 319−26.

28 Breslow A. Thickness, cross-sectional areas and depth of invasión in the prognosis of  cutaneous melanoma. Ann Surg 1970;172: 902−08.

29 Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199−206.

30 Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472−93.

31 Grob JJ, Schadendorf D, Lorigan P, et al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III. Eur J Cancer 2018; 91: 168−70.

32 de Vries E BF, Coebergh JW, Cerroni L, et al. Malignant melanoma: introduction. Lyon: IARC Press, 2006.

33 Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545: 175−80.

34 Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214−18.

35 Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2015; 47: 996−1002.

36 Brunner G, Reitz M, Heinecke A, et al. A nine-gene signatura predicting clinical outcome in cutaneous melanoa. J Cancer Res Clin Oncol 2013; 139: 249−58.

37 Griewank K, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Can Res 2013; 19: 3143−52.

38 Koopmans AE, Vaarwater J, Paridaens D, et al. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Brit J Can 2013; 109: 493−96.

39 Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191−99.

40 Daniels AB, Lee JE, MacConaill LE, et al. High throughput mass spectrometry-based mutation profiling of melanoma. Invest Ophthal Vis Sci 2012; 53: 6991−96.

41 Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957−59.

42 Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959−61.

43 Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Nat Can Inst 2014; 106 pii:dju246.

44 Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135−47.

45 Wiesner T, Kiuru M, Scott SN, et al. NF1 mutations are common in desmoplastic melanoma. Am J Surg Pathol 2015; 39: 1357−62.

46 Cosgarea I, Ugurel S, Sucker A, et al. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget 2017; 8: 40683−92.

47 Moon KR, Choi YD, Kim JM, et al. Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features. J Invest Dermatol 2018; 138: 933−45.

48 Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30−39.

49 Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23−34.

50 Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006−17.

51 Sunshine JC, Nguyen PL, Kaunitz GJ, et al. PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Can Res 2017; 23: 4938−44.

52 Zhao T, Li C, Wu Y, Li B, Zhang B. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS One 2017; 12: e0176822.

53 Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 2017; 123 (suppl 11): 2143−53.

54 Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350: 207−11.

55 Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 2016; 32: 1599−604.

56 Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE. Is physician detection associated with thinner melanomas? JAMA 1999; 281: 640–43.

57 Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331: 481.

58 Stang A, Jockel KH, Heidinger O. Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000−2015). Eur J Epidemiol 2018; 33: 303−12.

59 Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012; 118: 5395–402.

60 US Preventive Services Task Force. Screening for skin cancer. US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 188–93.

61 Stang A, Garbe C, Autier P, Jockel KH. The many unanswered questions related to the German skin cancer screening program. Eur J Cancer 2016; 64: 83−88.

62 Watts CG, Cust AE, Menzies SW, et al. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic. JAMA Dermatol 2015; 151: 178−86.

63 Watts CG, Cust AE, Menzies SW, et al. Cost-effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol 2017; 35: 63−71.

64 Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159: 669–76.

65 Tromme I, Sacre L, Hammouch F, et al. Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study. Br J Dermatol 2012; 167: 778–86.

66 Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol 2006; 126: 980–85.

67 Guitera P, Pellacani G, Longo C, et al. In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. J Invest Dermatol 2009; 129: 131–38.

68 Monheit G, Cognetta AB, Ferris L, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol 2011; 147: 188–94.

69 Malvehy J, Hauschild A, Curiel-Lewandrowski C, et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol 2014; 171: 1099–107.

70 Bono A, Bartoli C, Clemente C, et al. Ambulatory narrow excision for thin melanoma (< or = 2 mm): results of a prospective study. Eur J Cancer 1997; 33: 1330−32.

71 Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a prospective randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8−2.0 mm. Cancer 2000; 89: 1495−501.

72 Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757−66.

73 Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 2016; 17: 184−92.

74 Madu M, van Akkooi AC. Response to Wheatley et al. “Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation”, Cancer Treatment Reviews. Cancer Treat Rev 2016; 45: 76.

75 Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297: 627−30.

76 Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978; 41: 948−56.

77 Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regionale lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255−63.

78 Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. WHO Melanoma Programme. Lancet 1998; 351: 793−96.